Utility of B-type Natriuretic Peptide in Patients with Acute Respiratory Distress Syndrome

급성호흡곤란증후군 환자에 있어서 B-type Natriuretic Peptide의 유용성

  • Rhee, Chin Kook (Divison of Respiratory & Critical Care Medicine, Department of Internal Medicine, Kangnam St. Mary's Hospital) ;
  • Joo, Young Bin (Divison of Respiratory & Critical Care Medicine, Department of Internal Medicine, Kangnam St. Mary's Hospital) ;
  • Kim, Seok Chan (Divison of Respiratory & Critical Care Medicine, Department of Internal Medicine, Kangnam St. Mary's Hospital) ;
  • Park, Sung Hak (Divison of Respiratory & Critical Care Medicine, Department of Internal Medicine, Kangnam St. Mary's Hospital) ;
  • Lee, Sook Young (Divison of Respiratory & Critical Care Medicine, Department of Internal Medicine, Kangnam St. Mary's Hospital) ;
  • Koh, Yoon Seok (Divison of Cardiology Medicine, Department of Internal Medicine, Kangnam St. Mary's Hospital) ;
  • Kim, Young Kyoon (Divison of Respiratory & Critical Care Medicine, Department of Internal Medicine, Kangnam St. Mary's Hospital)
  • 이진국 (가톨릭대학교 의과대학 내과, 강남성모병원) ;
  • 주영빈 (가톨릭대학교 의과대학 내과, 강남성모병원) ;
  • 김석찬 (가톨릭대학교 의과대학 내과, 강남성모병원) ;
  • 박성학 (가톨릭대학교 의과대학 내과, 강남성모병원) ;
  • 이숙영 (가톨릭대학교 의과대학 내과, 강남성모병원) ;
  • 고윤석 (가톨릭대학교 의과대학 순환기 내과, 강남성모병원) ;
  • 김영균 (가톨릭대학교 의과대학 내과, 강남성모병원)
  • Received : 2007.03.09
  • Accepted : 2007.04.27
  • Published : 2007.05.30

Abstract

Background B-type natriuretic peptide (BNP) has been shown to be strong mortality predictors in a wide variety of cardiovascular syndromes. Little is known about BNP in patients with acute respiratory distress syndrome (ARDS). We studied whether BNP can predict mortality in patients with ARDS. Method Echocardiographic study was done to all patients with ARDS, and we excluded patient with low ejection fraction (less than 50%) or showing any features of diastolic dysfunction. 47 patients were enrolled between December, 2003 and February, 2006. Parameters including BNP were obtained within 24h hours at the time of enrollment. Result Mean BNP concentrations and APACHE II scores differed between the survivors and nonsurvivors (BNP, $219.5{\pm}57.7pg/mL$ vs $492.3{\pm}88.8pg/mL$; p=0.013, APACHE II score, $17.4{\pm}1.6$ vs $23.1{\pm}1.3$, p=0.009, respectively). With the use of the threshold value for BNP of 585 pg/mL, the specificity for the prediction of mortality was 94%. The threshold value for APACHE II of 15.5 showed sensitivity of 87%. 'APACHE II + $11{\times}logBNP$' showed sensitivity 63%, and specificity 82%, using threshold value for 46.14. Conclusion BNP concentrations and APCHE II scores were more elevated in nonsurvivors than survivors in patients with ARDS who have normal ejection fraction. BNP can predict mortality. Further study should be done.

연구배경: B-type natriuretic peptide(BNP)는 심인성 및 다른 쇼크 상태를 포함하는 심혈관 질환에서 사망을 예측하는 좋은 인자 중의 하나로 알려져 있다. 그러나, 급성호흡곤란증후군환자에서 이런 관계가 잘 알려져 있지 않는 바, 저자들은 BNP가 급성호흡곤란증후군 환자에서 사망을 예측할 수 있는 지를 연구하였다. 방 법: 본 연구는 전향적 관찰로 시행되었다. 급성호흡곤란증후군으로 진단된 환자들에게 심초음파 검사를 시행한 후, 좌심실 구획률이 50% 미만이거나 확장성 심부전 양상을 보인 환자들을 제외하였다. 2003년 12월부터 2006년 2월까지 총 47명의 환자가 채택되었다. 등록된 환자들은 24시간 내로 BNP를 포함한 여러 검사실 수치를 얻었으며, APACHE(Acute Physiology and Chronic Health Evaluation) II 점수를 구하였다. 결 과: BNP와 APACHE II 점수 평균값은 생존자군과 사망자군에서 유의한 차의를 보였다(BNP: $219.5{\pm}57.7pg/mL$ vs $492.3{\pm}88.8pg/mL$; p=0.013, APACHE II 점수: $17.4{\pm}1.6$ vs $23.1{\pm}1.3$, p=0.009). BNP 는 혈중 크레아티닌 수치와 양의 상관관계를 보였으나(r=0.374, p=0.01), 좌심실 구획률과는 유의한 관계가 없었다. Receiver operating characteristic 곡선상, BNP 수치를 585 pg/mL로 잡았을 때 사망을 예측하는데 있어서 94%의 특이도를 보였으며, APACHE II 점수의 경우에는 15.5를 기준으로 하였을 때 87%의 민감도를 보였다. 이 두 요소를 결합하여 '아파치II 점수+$11{\times}logBNP$' 수치를 계산하여 기준점을 46.14로 했을 경우, 사망 예측에 있어서 민감도 63%, 특이도 82%의 결과를 얻을 수 있었다. 결 론: 좌심실 기능 부전을 보이지 않는 급성호흡곤란증후군 환자에서 BNP 수치는 생존자군과 사망자군에서 유의한 차이를 보였으며 사망을 예측할 수 있었다. 향후 급성호흡곤란증후군 환자에 있어서 BNP와 관련된 연구가 더 필요하다고 생각된다.

Keywords

References

  1. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7 https://doi.org/10.1056/NEJMoa020233
  2. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-9 https://doi.org/10.1001/jama.288.10.1252
  3. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141: 367-74 https://doi.org/10.1067/mhj.2001.113215
  4. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9 https://doi.org/10.1161/01.CIR.93.11.1963
  5. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001;111:274-9 https://doi.org/10.1016/S0002-9343(01)00841-5
  6. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-7 https://doi.org/10.1016/S0009-8981(01)00578-2
  7. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88 https://doi.org/10.1515/CCLM.2001.093
  8. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004;6: 359-63 https://doi.org/10.1016/j.ejheart.2004.01.008
  9. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15 https://doi.org/10.1016/j.cccn.2003.08.016
  10. Maeder M, Ammann P, Rickli H, Diethelm M. Elevation of B-type natriuretic peptide levels in acute respiratory distress syndrome. Swiss Med Wkly 2003;133:515-8
  11. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Itoh M, Amaha K. Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care 1997;12:66-71 https://doi.org/10.1016/S0883-9441(97)90003-4
  12. Tung RH, Garcia C, Morss AM, Pino RM, Fifer MA, Thompson BT, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004;32:1643-7 https://doi.org/10.1097/01.CCM.0000133694.28370.7F
  13. Jefic D, Lee JW, Jefic D, Savoy-Moore RT, Rosman HS. Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 2005; 128:288-95 https://doi.org/10.1378/chest.128.1.288
  14. Bal L, Thierry S, Brocas E, Van de Louw A, Pottecher J, Hours S, et al. B-type natriuretic peptide (BNP) and N-terminal-proBNP for heart failure diagnosis in shock or acute respiratory distress. Acta Anaesthesiol Scand 2006;50:340-7 https://doi.org/10.1111/j.1399-6576.2006.00963.x
  15. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998;32:865-75 https://doi.org/10.1016/S0735-1097(98)00345-3
  16. Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unit. Am J Respir Crit Care Med 2002;166: 1310-9 https://doi.org/10.1164/rccm.200202-146CC
  17. Feigenbaum H, Armstrong WF, Ryan T. Feigenbaum's Echocardiography. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 209
  18. Phua J, Lim TK, Lee KH. B-type natriuretic peptide: issues for the intensivist and pulmonologist. Crit Care Med 2005;33:2094-13 https://doi.org/10.1097/01.CCM.0000178351.03327.9F
  19. Berendes E, Van Aken H, Raufhake C, Schmidt C, Assmann G, Walter M. Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth Analg 2001;93:676-82 https://doi.org/10.1097/00000539-200109000-00029
  20. Karmpaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra A, Talmor D, et al. Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 2007;131:964-71 https://doi.org/10.1378/chest.06-1247